13 result(s) displayed (1 - 13 of 13):
Big Pharma companies have been racing to acquire smaller biotech companies to bulk up on technology as they face patent losses on top-selling drugs. Here are some of the latest deals: Sanofi-Aventis SA agreed to buy British vaccine maker Acambis plc for £276 million ($547.8 million) in order to secure...
Posted on July 25, 2008 4:49 PM
The corporate dealmakers we talk to tend to have short, well-defined lists of things they like to use investment bankers for. See, for example, our post on the fact that Oracle Corp. accomplished its big, hostile takeover of BEA Systems Inc. without i-bankers, and also this very funny column by...
Posted on July 3, 2008 11:22 AM
With the medical world gearing up for a huge oncology conference in Chicago this weekend, Pfizer Inc. announced it had lured away Eli Lilly & Co.'s oncology business chief Garry Nicholson to run its own similar unit, which the drug giant formed earlier this year.With a string of high-profile duds...
Posted on May 15, 2008 2:25 PM
Ringo's tall order at PfizerNew Pfizer Inc. dealmaker William Ringo has quite a job ahead. The longtime drug executive -- he spent nearly three decades at Eli Lilly and Co., then was CEO at biotech Abgenix Inc., which he helped sell to Amgen Inc. for $2 billion, and most recently...
Posted on March 12, 2008 1:38 PM
A groundbreaking development deal between Eli Lilly and Hutchison MediPharma highlights the growing sophistication of China's pharma market.
Posted on December 15, 2007 1:29 PM
In the past, plant biotechnologists concentrated on crops used primarily for animal feed. Lately, though, the genetic engineers have turned to creating crops for biofuels. Startups in the field have worked largely on behalf of agricultural chemical giants. Monsanto Co., Dow AgroSciences LLC, the DuPont Agriculture & Nutrition division of...
Posted on December 15, 2007 10:39 AM
As the only big biotech dedicated to relentless acquisition, the company may point the way to consolidation in the sector.
Posted on October 15, 2007 7:53 PM
Every major pharmaceutical company is doing business in China either through joint ventures or wholly owned subsidiaries... also, we take a quick look at corporate venture capital.
Posted on October 15, 2006 5:27 PM
As pioneering biotech companies grow up, a few are using venture investments to keep tabs on early-stage technologies gestating inside their less mature counterparts.
Posted on April 15, 2006 5:18 PM
Google's pure VC play, new guidelines for DNA tech transfer, joint ventures in Russia, and heated competition in outsourcing.
Posted on April 15, 2006 4:03 PM
Laura McCluer on rebuilding alliances at CA; plus dealmaking at Vodafone, Bertelsmann, Nortel and GenVec.
Posted on April 15, 2006 3:32 PM
Eli Lilly and Co. spent $2.4 billion on life-science R&D last year, exploring everything from antisense technology to synthetic exendin-4. But the biggest experiment under way at the company isn't taking place in a lab or a clinic. And the results of that experiment - highly promising so far...
Posted on August 15, 2004 5:45 PM
Patricia Martin has been an energetic advocate, both inside and outside Eli Lilly and Co., for a simple idea. "There's life after the deal," she says. "And it's worth paying attention to." That in a nutshell is the mission of Lilly's Office of Alliance Management, which monitors, supports and helps...
Posted on August 15, 2004 2:44 PM
Movable Type search results powered by Fast Search
Juergen Lasowski
And the winners are...
